EMERYVILLE, Calif.,
Sept. 27, 2021 /PRNewswire/ --
Dynavax Technologies Corporation (Nasdaq: DVAX), a
biopharmaceutical company focused on developing and commercializing
vaccines, today announced that it will participate in the following
investor conferences.
2021 Cantor Virtual Global Healthcare
Conference
Dynavax Presentation: Thursday, September 30, 2021, 12:00 p.m. E.T.
Guggenheim 2nd Annual Vaccine and Infectious Disease
Conference
Fireside Chat: Tuesday,
October 5, 2021, 12:00 p.m.
E.T.
H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual
Conference
Fireside Chat: Wednesday,
October 13, 2021, 12:00 p.m.
E.T.
All the conferences are being held virtually. A live webcast of
each of the presentations will be available and may be accessed
through the "Events & Presentations" page on the "Investors"
section of the Company's website at
http://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial stage
biopharmaceutical company developing and commercializing novel
vaccines. The Company's first commercial product, HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the
U.S. and Europe for prevention of
infection caused by all known subtypes of hepatitis B virus in
adults age 18 years and older. Dynavax is also advancing CpG 1018
adjuvant as an advanced vaccine adjuvant through research
collaborations and partnerships. Current collaborations are focused
on adjuvanted vaccines for COVID-19, pertussis and universal
influenza. For more information, visit www.dynavax.com and
follow the company on LinkedIn.
Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-upcoming-investment-conferences-301385981.html
SOURCE Dynavax Technologies